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Introduction
Rapid and sustained efficacy of canakinumab (CAN) were
previously demonstrated in patients with systemic juvenile
idiopathic arthritis (SJIA) [1]. However, little is known
about potential differences in response to CAN treatment
between patients with vs. without SJIA-associated fever at
the time of the first CAN administration.
Objectives
To evaluate the long-term efficacy and safety profile of
CAN-naïve SJIA patients with and without SJIA-associated
fever.
Patients and methods
patients aged 2-20 years with SJIA with and without
SJIA associated fever at enrollment received open-label
CAN 4mg/kg s.c. every 4 wks. Every 3 months, response
to CAN was measured by adapted JIA ACR response
criteria (aACR/JIA); juvenile arthritis disease activity
score (JADAS); clinical inactive disease; clinical remis-
sion on medication (CRM, 6 months continuous clinical
inactive disease). Safety was assessed monthly.
Results
Data on 122/267 patients, 53 (43%) with and 69 (57%)
without SJIA associated fever, were available for analysis
with a median 94 wk study duration. At Wk4, ~75% of
both subgroups had responded (≥ aACR/JIA30), increas-
ing to 90% at Wk12. At Wk2, ~21% of both subgroups
had inactive disease; 44% at Wk8; 60% at Wk20 and
then 60-70% for the remainder of the trial. CRM was
achieved in about 29% of patients in both subgroups
with ~22% maintaining it for ≥12 consecutive months.
At baseline, the median JADAS score was 21.5 with
8 (7.5%) and 99 (92.5%) patients meeting the criteria for
moderate (JADAS >3.8 and ≤10.5) and high disease
activity (JADAS >10.5), respectively. At Day 15, the
median JADAS was 6.8 and 1.5 at the last assessment.
At the last assessment, 53 (48%) patients had inactive
disease (JADAS ≤ 1); 10 (9%) with low active disease
activity (JADAS >1 and ≤3.8); while 14 (13%) had mod-
erate and 31 (28%) with high disease activity. Infection
(0.56 infections/100 patient-days), typically involving
upper respiratory tract was the most common type of
adverse event. Fifteen patients discontinued due to an
AE and 40 had >1 SAE (mostly infections, macrophage
activation syndrome (MAS), or flare-associated) and no
deaths. Eight cases of MAS (0.013 events/100 patient-
days) were reported.
Conclusion
Canakinumab provides similar efficacy in SJIA patients
with and without SJIA-associated fever at treatment
onset. The long-term safety profile was acceptable and
similar to the pivotal program in SJIA children with
fever at enrollment.
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